Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in AI-driven immunology, announced new preclinical data for its cytomegalovirus (CMV) vaccine candidate, EVX-V1. The data were presented at a scientific conference, though specific details from the presentation are limited as the full content is behind a paywall.
According to the company's announcement, the preclinical study evaluated EVX-V1 in animal models and demonstrated the induction of robust immune responses. CMV is a common virus that can cause serious complications in immunocompromised individuals and during pregnancy, and there is currently no approved vaccine.
Evaxion's EVX-V1 is designed using the company's proprietary AI platform to identify novel antigens that could provide broad protection against CMV. The company plans to advance the program into clinical trials pending further evaluation and regulatory approvals.
As of July 14, 2026, no additional details on the specific immune responses or timelines for human trials have been publicly released beyond the conference presentation.
